Amneal Pharmaceuticals Inc - Ordinary Shares - Class A
AMRX
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.8B
Close$
$10.78
37.6% downside
Current Fair Value
37.6% downsideOvervalued by 37.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.80 Billion |
|---|---|
| Enterprise Value | $8.46 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.23 |
| Beta | 1.26 |
| Outstanding Shares | 319,200,000 |
Return
| Return on Equity | 288.05% |
|---|---|
| Return on Assets | 2.52% |
| Return on Invested Capital | -7.54% |
Valuation & Multiples
| P/E Ratio | 36.48 |
|---|---|
| PEG | 23.2 |
| Price to Sales | 2.47 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 3.53 |
| Enterprise Value to EBIT | -38.76 |
| Enterprise Value to Net Income | 88 |
| Total Debt to Enterprise | 0.33 |
| Debt to Equity | 84.54 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$0.22
Average shareholder expectationRevenue Estimate
$753.54 M
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$0.26
Average shareholder expectationRevenue Estimate
$805.03 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 226.60% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 14.89%▼ 36.13% |
|---|---|
| Total Invested | $847.07M▼ 57.37% |
| Investors Holding | 123▼ 195.00% |
ESG Score
No data